Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Steve Basta, President and Chief Executive Officer of Phathom Pharmaceuticals

“We are pleased to report continued solid revenue growth and improved operating profitability for the third quarter”

Steve Basta, President and Chief Executive Officer of Phathom Pharmaceuticals

“We continue to grow VOQUEZNA prescribing depth among GI providers and have implemented several initiatives designed to make it easier for physicians to prescribe and patients to obtain our first-in-class GERD treatment.”

Steve Basta, President and Chief Executive Officer of Phathom Pharmaceuticals

“These efforts build on our commercial momentum, which includes recently reaching the milestone of two million VOQUEZNA prescriptions filled.”

Sanjeev Narula, Chief Financial and Business Officer of Phathom Pharmaceuticals

“Our third quarter results reflect Phathom’s significant financial transformation, with revenue growth of 71% year over year and positive cash flow from operations for the second consecutive quarter”

Sanjeev Narula, Chief Financial and Business Officer of Phathom Pharmaceuticals

“We have established a stronger financial foundation through continued revenue growth and disciplined expense management, while maintaining the flexibility to invest in our commercial and clinical development priorities.”

Sanjeev Narula, Chief Financial and Business Officer of Phathom Pharmaceuticals

“We remain confident in our ability to meet our financial obligations and deliver on our full-year 2026 guidance.”